8-K: scPharmaceuticals Reports Strong Q4 Revenue Growth, Advances Pipeline

scPharmaceuticals announced its fourth quarter and full-year 2023 financial results, highlighting significant revenue growth for FUROSCIX and progress in its clinical development programs.

Summary

• scPharmaceuticals reported a net FUROSCIX revenue of $6.1 million for the fourth quarter of 2023, a 61% increase compared to the previous quarter.
• Full-year 2023 net FUROSCIX revenue reached $13.6 million.
• The company saw a 56% sequential increase in total FUROSCIX doses written, reaching 13,542 in Q4 2023.
• Filled FUROSCIX doses increased by 44% sequentially to 7,016 in the fourth quarter.
• The number of unique prescribers of FUROSCIX grew by 52% from launch through the end of the year, reaching 1,696.
• The gross-to-net discount for FUROSCIX decreased to 18% from launch through the end of the year, compared to 21% through the end of the third quarter.
• scPharmaceuticals ended 2023 with $76 million in cash, cash equivalents, and short-term investments.
• The company is on track to initiate a pivotal pharmacokinetic study in Q2 to support development of an 80mg/1mL auto-injector, with plans to submit an NDA by the end of 2024.
• Plans are underway to submit an sNDA to the FDA next month seeking expansion of the FUROSCIX indication to include patients suffering from chronic kidney disease.
• The sNDA submission to the FDA seeking to expand the FUROSCIX indication to include New York Heart Association Class IV heart failure patients is currently under review.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and progress in clinical development, but also highlights significant losses and increased expenses. The overall sentiment is positive but tempered by financial challenges.

Positives

• FUROSCIX revenue showed strong sequential growth in Q4 2023, indicating increasing market acceptance.
• The number of prescribers and doses written and filled increased significantly, demonstrating growing adoption of FUROSCIX.
• The gross-to-net discount improved, suggesting better pricing and revenue capture.
• The company has a solid cash position of $76 million, providing financial stability.
• The company is actively pursuing label expansion for FUROSCIX, which could significantly increase its market potential.
• The development of an auto-injector could further enhance the product's appeal and ease of use.

Negatives

• The company reported a net loss of $13.8 million for the fourth quarter of 2023, and a net loss of $54.8 million for the full year 2023.
• Selling, general, and administrative expenses increased significantly in both Q4 and full-year 2023.
• The company's cash reserves decreased from $118.4 million at the end of 2022 to $76 million at the end of 2023.
• The company anticipates that the gross-to-net discount will increase over time as contracting efforts mature.

Risks

• The company is dependent on the commercial success of FUROSCIX and its other product candidates.
• There are risks related to obtaining regulatory approval for product candidates.
• The company faces risks related to manufacturing and supply of sufficient product for commercialization.
• The company has a history of operating losses.
• Global economic factors and uncertainties could impact the company's operations.

Future Outlook

The company plans to initiate a pivotal pharmacokinetic study in Q2 to support development of an 80mg/1mL auto-injector, with an NDA submission targeted for the end of 2024. They also plan to submit an sNDA to the FDA next month seeking expansion of the FUROSCIX indication to include patients suffering from chronic kidney disease.

Management Comments

• We ended 2023 on a strong note, generating net FUROSCIX sequential revenue growth of 61%, which we believe reflects growing awareness and acceptance of FUROSCIX as a key component of a new heart failure treatment paradigm, stated John Tucker, President, and Chief Executive Officer of scPharmaceuticals.
• Our reported gross-to-net discount of 18% declined from launch through the end of Q4 as compared to 21% from launch through the end of Q3.
• We continue to anticipate that the GTN discount will increase over time as our contracting efforts continue to evolve and mature.
• We continue to advance these initiatives while at the same time successfully driving uptake of FUROSCIX, and both our fourth quarter results and leading indicators confirm that FUROSCIX acceptance and utilization among heart failure specialists is accelerating, Mr. Tucker concluded.

Industry Context

The announcement reflects a growing trend in the pharmaceutical industry towards developing and commercializing innovative drug delivery systems that can improve patient outcomes and reduce healthcare costs. The focus on subcutaneous self-administration aligns with the industry's move towards more patient-centric care models.

Comparison to Industry Standards

• The 61% sequential revenue growth for FUROSCIX in Q4 is a strong performance compared to many pharmaceutical companies in the early stages of product launch. For example, companies like Xeris Biopharma (XERS) have seen similar growth trajectories with their novel drug delivery systems, but the specific growth rates vary based on product and market dynamics.
• The gross-to-net discount of 18% is within the typical range for pharmaceutical products, but the company's anticipation of an increase over time is a common trend as companies negotiate with payers and expand market access. Companies like Amgen (AMGN) and AbbVie (ABBV) often see fluctuations in their gross-to-net discounts as they manage their product portfolios.
• The company's focus on expanding the FUROSCIX indication to include chronic kidney disease and NYHA Class IV heart failure patients is a strategic move to increase market penetration. This is similar to how companies like Novartis (NVS) and AstraZeneca (AZN) expand their product labels to reach a broader patient population.
• The development of an auto-injector is a common strategy to improve patient convenience and adherence, similar to how companies like Eli Lilly (LLY) and Novo Nordisk (NVO) have developed auto-injectors for their diabetes medications.

Stakeholder Impact

• Shareholders may be encouraged by the strong revenue growth and pipeline progress, but concerned about the net losses and cash burn.
• Employees may be impacted by the increase in employee-related costs, and the company's overall financial performance.
• Patients may benefit from the expanded indications and improved delivery methods for FUROSCIX.
• Suppliers and creditors may be impacted by the company's financial performance and cash position.

Next Steps

• Initiate a pivotal pharmacokinetic study in Q2 to support development of an 80mg/1mL auto-injector.
• Submit an sNDA to the FDA next month seeking expansion of the FUROSCIX indication to include patients suffering from chronic kidney disease.
• Continue to advance the sNDA submission to the FDA seeking to expand the FUROSCIX indication to include New York Heart Association Class IV heart failure patients.

Key Dates

Keywords

FUROSCIX, scPharmaceuticals, Heart Failure, Chronic Kidney Disease, Pharmaceuticals, Subcutaneous Injection, FDA, Revenue, Clinical Trials, Auto-injector